大成 Dentons: All about taxes
Trained as a tax specialist, he regularly advises healthcare companies but also major international groups on legal, tax and regulatory structuring issues. Le Guyader was formerly at Simmons & Simmons LLP, Ernst & Young Société d’Avocats and operated as Tax Director of the LEEM. He started his career at Laboratoires BOIRON as group tax specialist in charge of transfer prices. Le Guyader graduated from the ESC Lille and the University Paris I – Panthéon Sorbonne in Business and Tax Law, Public Law and Economics. He is also member of the Pharma Licensing Club France and administrator of the Association des Cadres de l’Industrie Pharmaceutique (ACIP).
Asit biotech: Expertise in vaccines
Before joining Asit biotech, he was CEO of Austrian company Intercell AG – which in 2013 merged with French company Vivalis create European vaccine and antibody leader Valneva. Zettlmeissl holds a doctoral degree in biochemistry from the University of Regensburg in Germany and did a post-doctoral fellowship in virology at the Institut Pasteur in Paris. Since 1985, Zettlmeissl has held various R&D and managerial positions at a number of international pharmaceutical companies, among others Managing Director of German vaccine company Chiron Behring.
In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. Zettlmeissl currently serves as non-executive director of Aeras, (USA). Until early 2015, he was chairman of GlycoVaxyn (Switzerland), an innovative vaccine company acquired by GlaxoSmithKline.
Erstwhile Asit biotech Chairman Béatrice De Vos has stepped down “to focus on new projects”.
Nanobiotix: Oncology expert
Dostie will be in charge of Nanobiotix’ operations, including development, manufacturing, market access, and sales, particularly for the lead product NBTXR3. The radio-enhancer could reach a CE market approval and a first phase II/III interim readout this year. Dostie, who holds a Bachelor of Science in Human Biology, joins the company after 25 years of international experience in the pharmaceutical industry, especially in market access and oncology. Previously, he worked as Oncology General Manager at Novartis Pharma GmbH in Germany.
Galapagos: To the clinic
Abi-Saab joins from Shire Pharmaceuticals, where he held various clinical development leadership positions, most recently Group Vice President, Global Clinical Development - Therapeutic Area Head, Gastro-intestinal, Endocrinology and Metabolism. Before Shire, the trained psychiatrist led the clinical development activities at Novartis, Abbott Laboratories, and Pfizer.
Pharmalink: Global chair
Carell previously held the position of CEO of Exeltis USA Inc. Before that, she was president of Meda US. Before joining Meda, she served as President and CEO of medtech company Q-Med AB, and spent more than four years working as General Manager at Actavis Pharmaceuticals in the Nordic region.
Oryzon Genomics: Alzheimer aid
Fillit is the Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation. He is also a clinical professor of geriatric medicine and palliative care, medicine, and neurosciences at The Icahn School of Medicine at Mount Sinai Medical Center, New York. Fillit has held faculty positions at Rockefeller University, SUNY-Stony Brook School of Medicine, and Cornell University School of Medicine, and has more than 300 scientific publications to his name. Together with Fillit, neurologist José Luis Molinuevo, Scientific Director of the Barcelonabeta Brain Research Center of the Pasqual Maragall Foundation, will also join Oryzon’s Scientific Advisory Board.